• @[email protected]
        link
        fedilink
        1022 days ago

        Meh. I have mine mostly under control so if they price it out of reach, so be it.

        But given that the article says it’s reformulating existing drugs to work here, they may be considerably cheaper than expected.

          • AmidFuror
            link
            fedilink
            122 days ago

            Yes, but the guy raising the concern may just have an ax to grind about the state of US healthcare.

  • @[email protected]
    link
    fedilink
    English
    14
    edit-2
    21 days ago

    The Fisher King to Perceval: “The real Holy Grail was the irritable bowel syndrome we acquired along the way.”

  • bean
    link
    fedilink
    1022 days ago

    Researchers have discovered a key biological pathway that drives inflammatory bowel disease (IBD) and other autoimmune disorders. This breakthrough centers on a gene called ETS2 that regulates the inflammatory behavior of immune cells called macrophages. The same pathway is thought to underlie conditions like ankylosing spondylitis and autoimmune liver and artery diseases. Existing cancer drugs called MEK inhibitors can dampen the activity of ETS2, suggesting a potential treatment approach. The researchers are now working to develop a targeted version of these drugs to treat IBD and related conditions, with clinical trials expected within 5 years. This discovery represents a major advance in understanding the fundamental causes of IBD and other immune disorders.

    Kagi Summarized